1. AddLife Q3 report October, 2017

2. AddLife introduction
A leading independent player mainly in the Nordic Life Science market
Markets and sells instruments, equipment, consumables and related services mainly to the healthcare sector in the Nordics
32 subsidiaries
Labtech and Medtech
Net sales SEK 2,276m 2

3. Our vision
AddLife strives to improve people’s lives by being a leading and value adding player within Life Science
Sofias kommentar; tycker att du här ska prata om vikten av en tydlig vision som styr organisationen framåt. En vision är inte bara ord och utan vad som ska ange riktningen för verksamheten varje dag. Som koncern är det er uppgift att tydliggöra visionen både internt till medarbetarna och till omvärlden. Det kan bland annat innebära att i all kommunikation knyta an till just visionen. Om du betonar detta när du pratar om den här bilden blir det sedan naturligt för Artur att ta resonemanget vidare. 3

4. Nordics is our home market
Other markets/operations
Production plant
Key markets 4

5. Products Advisory services Service and support Trainings
Customer offering
Products
Advisory services
Service and support
Trainings 5

6. Two business areas Labtech Products Customers Companies Medtech

7. Decentralized organization with entrepreneurial business acumen
Combine the small company’s…
With the large company’s…
Flexibility
Resources
”Small scale business – large scale wise”
Personality
Network
Effectiveness
Sustainability 7

8. Interim report Q3 2017 8

9. Highlights Q3 ”Strong summer quarter!”
Net Sales SEK 517m (409), +26%, organic, +9%
EBITA SEK 44m (31), +39%
EBITA-margin 8.5% (7.7)
R12 Months
Net Sales SEK 2,276 (1,799) +27%, organic, +8%
EBITA SEK 231 (155) +49%
EBITA-margin 10.1% (8.6) 9

10. Market update Q3
Positive development especially within research and health care. Stable within diagnostics. Larger product portfolio has enabled larger and more tenders within health care. Streamline warehouse and logistics in Medtech.
Developed well in the quarter from health care, diagnostics and research. Somewhat weaker demand still from pharma industry.
Developed favourably in research and diagnostics. Slightly weaker in health care. Delay in healthcare and social services reform until 2020 has led to some uncertainty in the market.
Continued positive trend in the quarter. High activity in the market from health care, home care and research.
Exports developed well for health care and home care. Weaker for advanced instruments mainly in the US. 10

11. Labtech Comments 11 Organic sales growth of 14% in Q and 10% YTD
Acquired sales growth of 9% in Q and 8% YTD
Positive development in diagnostics, especially in Finland.
Continued high grants to research, especially in Sweden and Norway
Still lower activity within pharmaceutical industry in Denmark.
Weaker demand than expected for own high-tech instruments.
EBITA increase during Q3 by 21%, corresponding to an EBITA-margin of 8.6% (8.6)
EBITA increase during YTD by 13%, corresponding to an EBITA-margin of 10.2% (10.8)
YoY +21% 11

12. Medtech Comments 12 Organic sales increase 3% in Q and increase 5% YTD
Acquired sales growth of 31% in Q and 29% YTD
Activity lower due to summer vacations
Increase in underlying demand in all Nordic countries except for Finland.
Streamline of warehouse and logistics
Positive demand within home care.
Krabat AS acquired in Q3
EBITA increased during Q3 by 80% corresponding to an EBITA- margin of 9.8% (7.3)
EBITA increased during YTD by 69% corresponding to an EBITA- margin of 9.3% (7.4)
YoY +34% 12

13. Profitability (P/WC) Cash Flow 13
3 months ending
9 months ending
(SEKm)
30 Sep 17
30 Sep 16
Profit after financial items 25 22
101 81
Adj. For non cash items 23 19 62 54
Income tax paid -8
-12
-24
-34
Changes in working capital
-13 -1
-28
-64
Cash flow from operating activities 27 28
111 37
Net investment in non-current assets -9 -5
-27
-39
Acquisitions and disposals
-47 -6
-296
-42
Cash flow from investing activities
-56
-11
-323
-81
Dividend paid -
-37
-277
Repurchase treasury shares
-33
Other financing activities 63 11
290
230
Period´s cash flow -3 4
-124
Return on working capital (P/WC) amounted to 65% (55)
Change in P/WC is attributable to the increased EBITA
Cash flow from operating activities amounted to SEK 111m (37)
Increased operating cash due to higher profit and more efficient working capital management 13

14. Balance sheet 14

15. Selected key financial ratios15

16. Q & A